Howland Capital Management LLC Buys New Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Howland Capital Management LLC bought a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the 1st quarter, according to its most recent filing with the SEC. The fund bought 1,632 shares of the biotechnology company’s stock, valued at approximately $211,000.

Several other large investors have also recently made changes to their positions in the company. Riggs Asset Managment Co. Inc. raised its position in Sarepta Therapeutics by 125.0% during the first quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 125 shares during the period. Central Pacific Bank Trust Division acquired a new position in Sarepta Therapeutics during the first quarter worth $414,000. Nordea Investment Management AB raised its position in Sarepta Therapeutics by 120.6% during the first quarter. Nordea Investment Management AB now owns 61,657 shares of the biotechnology company’s stock worth $8,004,000 after acquiring an additional 33,711 shares during the period. Connecticut Wealth Management LLC acquired a new position in Sarepta Therapeutics during the first quarter worth $261,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in Sarepta Therapeutics by 111.3% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 90,945 shares of the biotechnology company’s stock worth $12,131,000 after acquiring an additional 47,895 shares during the period. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Stock Down 0.3 %

Shares of SRPT traded down $0.52 during mid-day trading on Friday, hitting $151.59. 7,097 shares of the company’s stock were exchanged, compared to its average volume of 1,393,177. The company has a market cap of $14.33 billion, a price-to-earnings ratio of 1,382.82 and a beta of 0.89. Sarepta Therapeutics, Inc. has a fifty-two week low of $55.25 and a fifty-two week high of $173.25. The company has a debt-to-equity ratio of 1.18, a quick ratio of 3.44 and a current ratio of 4.05. The stock’s 50-day moving average is $134.56 and its 200-day moving average is $125.96.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.84. The business had revenue of $413.50 million for the quarter, compared to analysts’ expectations of $375.52 million. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The business’s quarterly revenue was up 63.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.44) earnings per share. On average, sell-side analysts anticipate that Sarepta Therapeutics, Inc. will post 3.76 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Robert W. Baird upped their price objective on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday, June 21st. BMO Capital Markets upped their target price on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the stock an “outperform” rating in a report on Monday, June 24th. Needham & Company LLC reaffirmed a “buy” rating and set a $235.00 target price on shares of Sarepta Therapeutics in a report on Thursday, June 27th. Evercore ISI upped their target price on shares of Sarepta Therapeutics from $139.00 to $185.00 and gave the stock an “in-line” rating in a report on Monday, June 24th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $165.00 target price on shares of Sarepta Therapeutics in a report on Friday, June 21st. Five analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, Sarepta Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $187.72.

Insider Activity at Sarepta Therapeutics

In related news, insider Dallan Murray sold 3,635 shares of the firm’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $140.00, for a total value of $508,900.00. Following the sale, the insider now owns 18,125 shares of the company’s stock, valued at $2,537,500. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Sarepta Therapeutics news, EVP Ryan Edward Brown sold 38,957 shares of the firm’s stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $161.61, for a total transaction of $6,295,840.77. Following the sale, the executive vice president now owns 17,129 shares of the company’s stock, valued at $2,768,217.69. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Dallan Murray sold 3,635 shares of the firm’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $140.00, for a total transaction of $508,900.00. Following the sale, the insider now directly owns 18,125 shares in the company, valued at approximately $2,537,500. The disclosure for this sale can be found here. Insiders have sold a total of 50,451 shares of company stock valued at $8,086,386 over the last 90 days. 7.70% of the stock is owned by corporate insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.